Endogenous molecules are fragile by nature. We make them metabolically resilient by design.
LathMize® Green Chemistry that changes how the body’s own molecules behave, without changing what they are.
More Life While Living
Less about how many trips around the sun you make. More about how great they are.
Bryleos builds for the people health innovation reaches last, if at all: veterans, people in recovery, and patients living with complex acute and chronic conditions.
Fragile twice over
The molecules that run human metabolism degrade on the shelf before they can be taken and are consumed before they can work. That fragility — not the biology — is what has held the field back.
Demonstrated in humans
In a randomized, placebo-controlled trial, our platform raised NAD inside cells by 53% versus placebo while circulating plasma NAD held steady. Published in GeroScience.
Four oral solid dose programs, one platform
BRY101
NAD+ medical food. Phase 1b dose finding to support wound healing.
Program details ↗BRY102
Neurodegenerative disease. 505(b)(1) IND candidate in preclinical development.
Program details ↗BRY103
Metabolic Modulator. 505(b)(2) candidate in IND-enabling studies.
Program details ↗BRY104
Oral peptide. 505(b)(1) IND candidate in preclinical development.
Program details ↗Taming the Wild West
A generation of research grade peptides is being sold on anecdote directly to the consumer. Almost none has been through a randomized controlled trial. We think that’s the opportunity, not the obstacle. BRY104 is being developed under an IND, in an oral solid dose form.